Treatment of Osteoporosis after Hip Fracture: Survey of the Korean Hip Society
- Author:
Jung-Wee PARK
1
;
Je-Hyun YOO
;
Young-Kyun LEE
;
Jong-Seok PARK
;
Ye-Yeon WON
Author Information
- Publication Type:Original Article
- From:Hip & Pelvis 2024;36(1):62-69
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:To assess current practice in the treatment of osteoporosis in patients who underwent treatment for hip fracture in South Korea.
Materials and Methods:A survey of 97 members of the Korean Hip Society, orthopedic hip surgeons who administer treatment for hip fractures in South Korea, was conducted. The survey was conducted for assessment of demographic data and perceptions regarding the management of osteoporosis in patients who have undergone treatment for hip fracture. Analysis of the data was performed using descriptive statistical methods.
Results:The majority of participants were between the age of 41 and 50 years, and 74% were practicing in tertiary hospitals. Testing for serum vitamin D levels (82%) was the most commonly performed laboratory test. Calcium and vitamin D were prescribed for more than 80% of patients by 47% and 52% of participants, respectively. Denosumab was the most commonly used first-line treatment option for osteoporosis in hip fracture patients. Bisphosphonate was most often perceived as the cause of atypical femoral fractures, and the most appropriate time for reoperation was postoperative 12 months. Teriparatide was most preferred after cessation of bisphosphonate and only prescribing calcium and vitamin D was most common in high-risk patients for prevention of atypical femoral fracture.
Conclusion:The results of this study that surveyed orthopedic hip surgeons showed that most participants followed the current strategy for management of osteoporosis. Because the end result of osteoporosis is a bone fracture, active involvement of orthopedic surgeons is important in treating this condition.
